Hormonal
Periodic administration of the senolytic drug combination Dasatinib and Quercetin (D+Q) selectively eliminates senescent cells, thereby extending healthspan and delaying age-related pathologies in murine models.
The research suggests that a specific combination of Dasatinib and Quercetin, taken periodically (weekly) at specific doses, can clear senescent cells and extend healthspan in mice. While promising, this is preclinical data. Humans should not self-administer these drugs without medical supervision, as the long-term safety and optimal dosing for humans are not yet established.
Periodic drug administration extended healthspan in Ercc1(delta)/Delta mice, delaying age-related symptoms and pathology, osteoporosis, and loss of intervertebral disk proteoglycans.
Why this rating
Strong preclinical evidence in multiple mouse models (aged, progeroid, irradiated) with consistent functional improvements, though human data is not yet presented.
Source
The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
Yi Zhu et al. · Aging Cell · 2015
DOI 10.1111/acel.12344
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →